April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its
Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that integrates high‑resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions. This positions Abbott at the forefront of AI-guided cardiovascular care, potentially making OCT a more intuitive, workflow-friendly tool for treating challenging coronary disease cases. Next, we’ll...